Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis

Shots:

• The P-II clinical trial evaluates FB-401 vs PBO in patients with AD
• The trial did not meet its 1EPs of EASI-50 (50% improvement in AD disease severity as measured by EASI)
• Additionally, positive trends were identified in key 2EPs i.e., improvement in disease severity @16wks., patients achieving the EASI-90 EPs (27.6% vs 20.5%) while (38.2% vs 29.5%) in IGA success (2 point reduction and clear or almost clear). The 1EPs of EASI-50 was achieved in 58% vs 60% of patients

Click here to­ read full press release/ article | Ref: Business Wire | Image: Forte Bioscience